EGFR and non-small cell lung carcinoma: In the H596 NSCLC xenograft model, the anti-tumor efficacy of ficlatuzumab was verified and increased with combination therapy with gefitinib and cetuximab, an EGFR inhibitor, compared with single agent treatment [178].